 compar studi hemaccel albumin infus total paracentesi cirrhot patient refractori ascit cirrhot patient refractori ascit one-sess large-volum paracentesi group first group human albumin second group hemaccel dose compar oncot power group incid complic recurr massiv ascit hospit dismiss surviv rate incid complic paracentesi probabl readmiss hospit ascit probabl surviv entri studi group multivari analysi paramet treatment modal absolut unrespons diuret independ predictor mortal result hemaccel infus albumin infus total paracentesi cirrhot patient refractori ascit